跳至主要内容
临床试验/2025-523589-26-00
2025-523589-26-00招募中4 期

Infusion of Furosemide to Improve Diuretic Efficiency in Acute Heart Failure (INFUSE-AHF)

Region Midtjylland7 个研究点 分布在 1 个国家目标入组 436 人开始时间: 2026年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
436
试验地点
7
主要终点
Net weight loss 3 days (≈72 hours) after randomisation

研究概览

简要总结

To determine if there is a difference in the diuretic treatment effect in acute heart failure between intravenous administration of furosemide by either continuous infusion preceded by a loading dose or bolus injections three times a day.

研究设计

分配方式
Na
主要目的
Follow-up phase
盲法
None

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Clinical diagnosis of acute heart failure with volume overload
  • ≥ 1 sign of volume overload
  • Anticipated intravenous furosemide ≥ 3 days
  • Age ≥ 18 years

排除标准

  • Patient requiring treatment with inotropes or vasopressors
  • Current or planned use of renal replacement therapy or ultrafiltration
  • Patient with a renal transplant
  • Patients who are pregnant or breastfeeding
  • Severe hypokalaemia (<2.5 mmol/L) or severe hyponatremia (<125 mmol/L)
  • Allergy to furosemide and its components

研究组 & 干预措施

FUROSEMIDE

Test

干预措施: FUROSEMIDE (Drug)

结局指标

主要结局

Net weight loss 3 days (≈72 hours) after randomisation

Net weight loss 3 days (≈72 hours) after randomisation

次要结局

  • Net weight loss 2 days (≈48 hours) after randomisation
  • Change in dyspnea on a Visual Analogue Scale 3 days (≈72 hours) after randomisation
  • Days alive out-of-hospital to Day 30
  • Length of stay

研究者

发起方
Region Midtjylland
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Esben Merrild

Scientific

Region Midtjylland

研究点 (7)

Loading locations...

相似试验